- Home
- UCL vs BLRX Comparison
UCL vs BLRX Comparison
Compare UCL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- BLRX
- Stock Information
- Founded
- UCL 2014
- BLRX 2003
- Country
- UCL Hong Kong
- BLRX Israel
- Employees
- UCL N/A
- BLRX N/A
- Industry
- UCL Telecommunications Equipment
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- BLRX Health Care
- Exchange
- UCL Nasdaq
- BLRX Nasdaq
- Market Cap
- UCL 70.6M
- BLRX 15.3M
- IPO Year
- UCL 2020
- BLRX 2011
- Fundamental
- Price
- UCL $1.92
- BLRX $4.70
- Analyst Decision
- UCL
- BLRX Strong Buy
- Analyst Count
- UCL 0
- BLRX 2
- Target Price
- UCL N/A
- BLRX $19.00
- AVG Volume (30 Days)
- UCL 51.0K
- BLRX 77.4K
- Earning Date
- UCL 08-13-2025
- BLRX 08-14-2025
- Dividend Yield
- UCL N/A
- BLRX N/A
- EPS Growth
- UCL N/A
- BLRX N/A
- EPS
- UCL 0.09
- BLRX N/A
- Revenue
- UCL $92,256,000.00
- BLRX $22,340,000.00
- Revenue This Year
- UCL $6.09
- BLRX N/A
- Revenue Next Year
- UCL $7.01
- BLRX N/A
- P/E Ratio
- UCL $20.26
- BLRX N/A
- Revenue Growth
- UCL 7.65
- BLRX 91.68
- 52 Week Low
- UCL $0.80
- BLRX $2.30
- 52 Week High
- UCL $3.30
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- UCL 58.25
- BLRX 57.56
- Support Level
- UCL $1.79
- BLRX $4.05
- Resistance Level
- UCL $1.96
- BLRX $4.64
- Average True Range (ATR)
- UCL 0.14
- BLRX 0.38
- MACD
- UCL -0.02
- BLRX -0.01
- Stochastic Oscillator
- UCL 33.97
- BLRX 86.17
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.